Coherus Oncology (CHRS) Operating Margin Growth (3y) (2016 - 2026)

Coherus Oncology (CHRS) Operating Margin Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,942.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Coherus Oncology 195.05 Mn 28.00 Mn 8.50 Mn -8,481.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -8,481.00
Dec 31, 2025 -24,636.00
Sep 30, 2025 -20,603.00
Jun 30, 2025 -37,042.00
Mar 31, 2025 -46,329.00
Dec 31, 2024 -53,297.00
Sep 30, 2024 -73,448.00
Jun 30, 2024 -35,730.00
Mar 31, 2024 -273,549.00
Dec 31, 2023 -9,016.00
Sep 30, 2023 -7,261.00
Jun 30, 2023 -10,697.00
Mar 31, 2023 -24,403.00
Dec 31, 2022 -14,990.00
Sep 30, 2022 -22,352.00
Jun 30, 2022 -10,612.00
Mar 31, 2022 -8,987.00
Jun 30, 2020 409,371.00
Mar 31, 2020 4.50 Mn
Dec 31, 2019 874,015.00